Equibles does not estimate personal net worth.
Get an email with a short summary when Candel Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CADL alertsThe proxy statement of Candel Therapeutics, Inc. reports total compensation of $613,231 for Seshu Tyagarajan in fiscal 2024, including a base salary of $401,361. Disclosed compensation is on record for 3 fiscal years. Seshu Tyagarajan has spoken on 1 investor event across 1 company, most recently for Candel Therapeutics, Inc. on May 15, 2026. Candel Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Candel Therapeutics, Inc. includes Paul Peter Tak (CEO and Board Member), Charles Schoch (CFO), Jason Amello (CFO) and 7 others.
“So I'm Seishu Tiagarajan, CTDO for KENDEL. We have continued to make progress on the timelines that we had shared with the group earlier.”
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Candel Therapeutics, Inc. (CADL) | Ph.D., RAC Chief Technical and Development Officer | $401,361 | $613,231 |
| 2022 | Candel Therapeutics, Inc. (CADL) | Ph.D., RACChief Technical and DevelopmentOfficer | $235,385 | $916,020 |
| 2021 | Candel Therapeutics, Inc. (CADL) | Ph.D., RACChief Technical and DevelopmentOfficer | — | — |
